The global nephroblastoma therapeutics is slated to reach a valuation of USD 2.12 billion in 2023. According to Future Market Insights, the market is expected to grow at a 9.88% CAGR until 2033, valued at USD 5.44 billion.
The key factors driving the revenue growth of the nephroblastoma therapeutics market are the rapidly increasing population of newborn babies and increased funding for healthcare infrastructure and facilities by the government. Furthermore, extensive research and development activities in the cancer disease and an increase in awareness amongst the people regarding cancer are also expected to support the market revenue growth.
The high cost associated with the treatment and diagnosis of cancer is the major factor restraining the revenue growth of the market. In addition, side effects related to the treatment of cancer are also expected to hamper the revenue growth of the global Wilms market to some extent.
Extensive research and development activities in the field of cancer treatment and the use of modern technology for research purposes are expected to create significant revenue growth opportunities in the market. Many key players are working on developing a novel cancer treatment that is expected to create lucrative revenue growth opportunities for new entrants in the market.
North America is expected to account for the largest revenue share in the global nephroblastoma therapeutics market because of the increasing prevalence of the nephroblastoma disease in children followed by the Asia-Pacific is expected to be the fastest growing market in terms of revenue, due to the increasing prevalence of the Wilms tumor and a rapidly increasing population of newborn babies in this region.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2023) | USD 2.12 billion |
| Projected Forecast Value (2033) | USD 5.44 billion |
| Growth rate | 9.88% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global nephroblastoma therapeutics market grew at a CAGR of 8.88% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Although most patients with a histological diagnosis of Wilms tumor do well with current treatment, approximately 10% of patients have histopathological features that are associated with a worse prognosis, and in some types, with a high incidence of relapse and death.
Nowadays, improved risk stratification has divided the population of patients into small subgroups, creating the challenge of designing and executing clinical trials that are sufficiently powered to demonstrate the desired outcomes. The fruits of stepped-up international collaboration are beginning to be realized, with the discovery of new genes, biological markers, and therapeutic targets. The benefits of COG-SIOP collaboration will hopefully translate into the application of evidence-based diagnostic and therapeutic approaches in low-income countries.
Increase in approvals of regulatory bodies
Key players in the market are focused on receiving approvals from regulatory bodies for drugs used to treat nephroblastoma is expected to drive the market growth over the forecast period.
Frequent regulatory approvals for new nephroblastoma treatments are expected to propel the growth of the global nephroblastoma treatment market during the forecast period. Market players are focusing on approvals from regulatory authorities for new drugs.
Focusing on the growth of R&D activities
Moreover, market players are focusing on R&D activities for new treatments, which is also expected to augment the growth of the global nephroblastoma treatment market during the forecast period. For instance, in August 2022, Children’s Oncology Group studying the combination of chemotherapy and surgery effects on young patients suffering from Wilms tumor revealed to be in Phase 3 trial and that the study is likely to be completed by end of the year 2023.
Principal Consultant
The high cost of treatment leads acts as a restraining factor
The major factor that hinders the growth of the global nephroblastoma therapeutics market includes the high cost of nephroblastoma. According to an article published by the American Society of Clinical Oncology, the cost for the full course of treatment was determined between USD 1490 and USD 2093 for a patient suffering from nephroblastoma.
Favorable reimbursement policies offering moneymaking opportunities in the United States
The United States is known for its healthcare infrastructure and favorable reimbursement scenario as both of them are expected to push the demand for nephroblastoma treatment shortly. A rise in the incidence of different types of tumors, rapid adoption of novel cancer treatments, and an increase in investment in medical research and development are also expected to favor market growth in the future.
Increasing investments in healthcare infrastructural development will favor market growth in Japan
Demand for nephroblastoma treatment is expected to be primarily driven by an increasing focus on healthcare infrastructure development and a rise in investments in medical R&D, the growing awareness regarding nephroblastoma, an increase in spending patterns on health and fitness, and the growing availability of novel cancer treatments with a rise in the number of cases are the factors that will augment the development of the market over the next ten years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Dactinomycin is said to hold a dominant share of the market
According to the reports of FMI, of 13 children treated with dactinomycin in addition to nephrectomy and postoperative radiotherapy, 92% (12 of 13) are living and free of tumors. It was concluded that the survival of children with nephroblastoma is markedly prolonged by the administration of dactinomycin at the time of diagnosis. The beneficial effect of dactinomycin was attributed to the ‘cidal’ action of this drug on small or poorly established metastases.
The demand for hospital pharmacies will be more during the forecast period.
According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the growing number of people visiting hospitals for advice on treatment related to nephroblastoma, the hospital pharmacy is anticipated to dominate the worldwide nephroblastoma therapeutics market. As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
The Soonicorns - soon to be Unicorns - are the handful of highly valued startups that have successfully grown out of their nascency to attract valuations of over a few hundred million. Watch out for these companies in the coming years as they take on the journey to becoming elite Unicorns.
Penn Medicine’s Abramson Cancer Center published early data from the first USA clinical trial of CRISPR-edited immune cells, showing that genetically editing the T cells of human cancer patients and infusing the cells back into the patients appeared safe and feasible. Investigators reported infusing three participants - two with multiple myeloma and one with sarcoma.
Some of the prominent players in the global market for Nephroblastoma Therapeutics Market treatment are
Some of the important developments of the key players in the market are
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 9.88% from 2023 to 2033 |
| Market value in 2023 | USD 2.12 Billion |
| Market value in 2033 | USD 5.44 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Type, Drug type, Distribution channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled | Merck & Co., Inc.; Recordati Rare Diseases; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Cipla Inc.; Actiza Pharmaceutical Private Limited; Teva Pharmaceutical Industries Ltd.; Alvogen; Accord Healthcare Ireland Ltd.; Amneal Pharmaceuticals LLC. |
| Customization Scope | Available on Request |
Collaborations are speeding up drug development and treatment access.
Continuous R&D activities are supporting the discovery of novel treatments.
Personalized treatment approaches, innovative drug combinations, and minimally invasive surgical techniques.
Growing awareness, and breakthroughs in treatment choices are driving the industry.
North America and Europe are prominent regions in the market.
1. Executive Summary | Nephroblastoma Therapeutics Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2032 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Type 5.1. Favorable histology 5.2. Anaplastic histology 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Drug Type 6.1. Dactinomycin 6.2. Doxorubicin 6.3. Vincristine 6.4. Cyclophosphamide 6.5. Etoposide 6.6. Irinotecan 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2032, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Merck & Co., Inc. 18.2. Recordati Rare Diseases 18.3. Pfizer Inc. 18.4. Sun Pharmaceutical Industries Ltd. 18.5. Cipla Inc. 18.6. Actiza Pharmaceutical Private Limited 18.7. Teva Pharmaceutical Industries Ltd. 18.8. Alvogen 18.9. Accord Healthcare Ireland Ltd. 18.10. Amneal Pharmaceuticals LLC. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Nephroblastoma Therapeutics Market
